Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Charles Redfern

    TitleAssociate Physician
    SchoolUniversity of California, San Diego
    DepartmentFamily Medicine and Public Health
    Address200 W. Arbor Drive #8204
    CA San Diego 92103
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      G PROTEIN SIGNALING AND TISSUE PROLIFERATION
      NIH/NCI K08CA071779Jul 5, 1996 - Jun 30, 2001
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern C, Shore ND. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 1; 21(17):3862-9. PMID: 25925891.
        View in: PubMed
      2. Eppler S, Gordon MS, Redfern C, Trudeau C, Xu N, Han K, Lum BL. Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Anticancer Drugs. 2015 Apr; 26(4):448-55. PMID: 25643049.
        View in: PubMed
      3. Xu N, Redfern C, Gordon M, Eppler S, Lum BL, Trudeau C. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1251-60. PMID: 25344761.
        View in: PubMed
      4. Boasberg PD, Redfern C, Daniels GA, Bodkin D, Garrett CR, Ricart AD. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011 Aug; 68(2):547-52. PMID: 21516509.
        View in: PubMed
      5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern C, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29; 363(5):411-22. PMID: 20818862.
        View in: PubMed
      6. Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother. 2010 Feb-Mar; 33(2):178-84. PMID: 20145546.
        View in: PubMed
      7. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern C, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007 Feb 20; 25(6):669-74. PMID: 17308271.
        View in: PubMed
      8. Small EJ, Schellhammer PF, Higano CS, Redfern C, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1; 24(19):3089-94. PMID: 16809734.
        View in: PubMed
      9. Redfern C, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006 Jul 1; 24(19):3107-12. PMID: 16754937.
        View in: PubMed
      10. Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, Bridgewater J, Moore M, Cassidy J, Coleman R, Coxon F, Redfern C, Jones JJ, Hawkins R, Northfelt D, Sreedharan S, Valone F, Carmichael J. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol. 2006 Mar; 17(3):437-42. PMID: 16311275.
        View in: PubMed
      11. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun; 27(3):232-9. PMID: 15076141.
        View in: PubMed
      12. Scearce-Levie K, Coward P, Redfern C, Conklin BR. Tools for dissecting signaling pathways in vivo: receptors activated solely by synthetic ligands. Methods Enzymol. 2002; 343:232-48. PMID: 11665570.
        View in: PubMed
      13. Scearce-Levie K, Coward P, Redfern C, Conklin BR. Engineering receptors activated solely by synthetic ligands (RASSLs). Trends Pharmacol Sci. 2001 Aug; 22(8):414-20. PMID: 11479004.
        View in: PubMed
      14. Baker AJ, Redfern C, Harwood MD, Simpson PC, Conklin BR. Abnormal contraction caused by expression of G(i)-coupled receptor in transgenic model of dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2001 Apr; 280(4):H1653-9. PMID: 11247776.
        View in: PubMed
      15. Redfern C, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevicz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci U S A. 2000 Apr 25; 97(9):4826-31. PMID: 10781088.
        View in: PubMed
      16. Redfern C, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, Conklin BR. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat Biotechnol. 1999 Feb; 17(2):165-9. PMID: 10052353.
        View in: PubMed
      Charles's Networks
      Concepts
      Derived automatically from this person's publications.
      See all (117) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (1) people
      _
      Similar People
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _